Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study

IF 5.4 3区材料科学 Q2 CHEMISTRY, PHYSICAL

ACS Applied Energy Materials Pub Date : 2024-08-13 DOI:10.1016/j.oraloncology.2024.106981

Rui Yang , Ruichen Li , Xiaoshuang Niu , Yang Zhao , Li Yan , Shu Tian , Yi Zhu , JianJian Qiu , Xiaoshen Wang

{"title":"Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study","authors":"Rui Yang , Ruichen Li , Xiaoshuang Niu , Yang Zhao , Li Yan , Shu Tian , Yi Zhu , JianJian Qiu , Xiaoshen Wang","doi":"10.1016/j.oraloncology.2024.106981","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><p>To evaluate the effectiveness and safety of low-dose gemcitabine and metronomic capecitabine in combination with tislelizumab for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who have previously received other anti-PD-1 therapies.</p></div><div><h3>Methods</h3><p>This retrospective, observational study included patients with RM-NPC who had prior treatment with anti-PD-1 therapy and subsequently received tislelizumab along with low-dose gemcitabine and metronomic capecitabine between March 2019 and August 2023. Progression-free survival (PFS) was estimated using the Kaplan-Meier method.</p></div><div><h3>Results</h3><p>Among 25 eligible patients, 8 (20%) achieved a complete response (CR). The objective response rate (ORR) was 68%, and the disease control rate (DCR) was 80%. The 1-year PFS rate was 78%. All patients experienced treatment-related adverse events, which were all grade 1 or 2.</p></div><div><h3>Conclusion</h3><p>The combination of tislelizumab with low-dose gemcitabine and metronomic capecitabine demonstrated promising antitumor effectiveness in RM-NPC patients who had failed previous anti-PD-1 therapy, with a manageable safety profile.</p></div>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1368837524002999/pdfft?md5=ecea1eb749389216a7609aa65f30bfc0&pid=1-s2.0-S1368837524002999-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368837524002999","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

To evaluate the effectiveness and safety of low-dose gemcitabine and metronomic capecitabine in combination with tislelizumab for patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who have previously received other anti-PD-1 therapies.

Methods

This retrospective, observational study included patients with RM-NPC who had prior treatment with anti-PD-1 therapy and subsequently received tislelizumab along with low-dose gemcitabine and metronomic capecitabine between March 2019 and August 2023. Progression-free survival (PFS) was estimated using the Kaplan-Meier method.

Results

Among 25 eligible patients, 8 (20%) achieved a complete response (CR). The objective response rate (ORR) was 68%, and the disease control rate (DCR) was 80%. The 1-year PFS rate was 78%. All patients experienced treatment-related adverse events, which were all grade 1 or 2.

Conclusion

The combination of tislelizumab with low-dose gemcitabine and metronomic capecitabine demonstrated promising antitumor effectiveness in RM-NPC patients who had failed previous anti-PD-1 therapy, with a manageable safety profile.

查看原文本刊更多论文

吉西他滨、卡培他滨和替莱珠单抗治疗既往抗PD-1治疗失败的复发/转移性鼻咽癌：回顾性研究

目的评估低剂量吉西他滨和甲氧卡培他滨联合替斯利珠单抗治疗既往接受过其他抗PD-1疗法的复发性或转移性鼻咽癌（RM-NPC）患者的有效性和安全性。方法这项回顾性观察研究纳入了曾接受过抗PD-1疗法治疗的RM-NPC患者，他们随后在2019年3月至2023年8月期间接受了替舒利珠单抗以及小剂量吉西他滨和节律卡培他滨治疗。结果在25名符合条件的患者中，8人（20%）获得了完全应答（CR）。客观反应率（ORR）为68%，疾病控制率（DCR）为80%。1年PFS率为78%。结论对于既往抗PD-1治疗失败的RM-NPC患者，tislelizumab与小剂量吉西他滨和甲粒卡培他滨的联合治疗显示出良好的抗肿瘤效果，且安全性可控。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Energy Materials Materials Science-Materials Chemistry

CiteScore

10.30

自引率

6.20%

发文量

1368

期刊介绍： ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.